Tango Therapeutics: Combo Data With Revolution's RAS Inhibitor Whets Risk Appetite
Source: SeekingAlpha
2026-06-09 15:10:32 ET
Investment Overview
I shared my first bullish take on Tango Therapeutics, Inc. ( TNGX ) with Seeking Alpha readers back in January 2024 , and the stock is up nearly 150% since. In subsequent notes in September 2024 and January 2025 , I also gave stock Buy ratings, although by January 2025, the stock had sunk in value from $12.5 (in Jan 2024) to <$3 per share, down <75% since my first Buy rating....
Read the full article on Seeking Alpha
For further details see:
Tango Therapeutics: Combo Data With Revolution's RAS Inhibitor Whets Risk Appetite
Erasca Inc.
NASDAQ: ERAS
ERAS Trading
0.24% G/L:
$19.07 Last:
2,040,913 Volume:
$19.36 Open:
ERAS Latest News
July 20, 2026 11:30:00 am
Kaplan Fox Encourages Investors of Erasca, Inc. (ERAS) Who Suffered Losses to Contact the Firm Before August 10, 2026
July 03, 2026 08:00:00 pm
ERAS INVESTOR REMINDER: Erasca, Inc. Investors Have Until August 10, 2026 to Seek Lead Plaintiff Role
$3,659,231,070
262,117,305
1.32%
40
N/A
Biotechnology & Life Sciences
Healthcare
US
San Diego
